CORAL SPRINGS, Fla., Jan. 25, 2018 (GLOBE NEWSWIRE) -- —via OTC PR WIRE-- -- Nutra Pharma Corporation (OTC:NPHC), a biotechnology company developing drugs for the treatment of Multiple Sclerosis (MS) and HIV and that also markets the over-the-counter (OTC) pain drugs; Nyloxin® and Pet Pain-Away™, announced today that they have updated their corporate website at www.nutrapharma.com as well as their product website at www.nyloxin.com. The newly redesigned websites offer quick and easy access to essential information and features that offer a more comprehensive understanding of the Company's products and services. The website also has a comprehensive investor section with updated company news and events, financial and stock information, SEC filings and corporate governance information.
"We’ve been extremely busy with product rollouts, distribution partnerships and international registrations for our OTC drugs," stated Rik J Deitsch, CEO of Nutra Pharma. "Included in all of this activity is the launch of our newly-designed Nutra Pharma website," he continued. "We initially redesigned the Nyloxin website a few months ago to feature ‘Corky’ our friendly cobra handing out Nyloxin samples to people of need. Now, the Nutra Pharma website is more user-friendly, easier to navigate and easier to update with the intention to keep our shareholders and customers informed on a timely basis. This new, visually appealing website is essential to stay current as we expand sales and marketing efforts for our OTC products through international distributors and US Federal government buyers," he concluded.
Nutra Pharma recently announced expanded sales and marketing plans for Nyloxin® and Pet Pain-Away™. This included a direct marketing campaign for Pet Pain-Away™ and, more recently, a partnership with EuroAmerican IP to register Nyloxin® through their Federal Supply Schedule contract. The successful addition of Nyloxin® to the Federal Supply Schedule will allow for sale to buyers within the Federal government in response to the opioid crisis and the Opiate Reduction Initiative.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-Away™. For additional information about Nutra Pharma, visit:
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The updated websites should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
Nutra Pharma Corp.